Clinical trial
Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory…
NCT00089284 · Northwestern University, Other · Terminated
Key facts
| NCT number | NCT00089284 |
|---|---|
| Title | Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL |
| Official title | A Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20 Positive Non-Hodgkin's Lymphoma (NHL): Combining 90-Yttrium- Zevalin and the Redox- Modulating Agent, Motexafin Gadolinium (MGd) |
| Lead sponsor | Northwestern University, Other |
| Collaborators | Robert H. Lurie Cancer Center |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma (NHL) |
| Intervention type | Drug |
| Interventions | Rituxan, motexafin gadolinium, 111Indium-Zevalin and 90Yttrium-Zevalin |
| Enrollment | 30 |
| Start date | Oct 28, 2003 |
| Primary completion | Jan 1, 2007 |
| Completion | Aug 20, 2008 |
| First posted | Aug 5, 2004 |
| Last update posted | Aug 14, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: